Growth Metrics

Gilead Sciences (GILD) Share-based Compensation Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Stock Comp. Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 7.06%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -0.66%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 12.36%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 8.46%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 16.86%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 9.73%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 37.34%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 6.17%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 9.73%
Dec 31, 2025 9.75%
Sep 30, 2025 11.04%
Jun 30, 2025 10.89%
Mar 31, 2025 17.15%
Dec 31, 2024 11.77%
Sep 30, 2024 8.10%
Jun 30, 2024 8.15%
Mar 31, 2024 10.39%
Dec 31, 2023 7.68%
Sep 30, 2023 5.30%
Jun 30, 2023 11.20%
Mar 31, 2023 5.38%
Dec 31, 2022 3.49%
Sep 30, 2022 1.22%
Jun 30, 2022 -1.75%
Mar 31, 2022 -3.13%
Dec 31, 2021 -3.15%
Sep 30, 2021 -4.77%
Jun 30, 2021 -12.99%
Mar 31, 2021 -14.19%
Dec 31, 2020 -21.59%
Sep 30, 2020 15.25%
Jun 30, 2020 12.18%
Mar 31, 2020 16.58%
Dec 31, 2019 15.46%
Sep 30, 2019 19.47%
Jun 30, 2019 22.35%
Mar 31, 2019 17.57%
Dec 31, 2018 21.74%
Sep 30, 2018 26.85%
Jun 30, 2018 37.95%
Mar 31, 2018 33.72%
Dec 31, 2017 52.06%
Sep 30, 2017 4.16%
Jun 30, 2017 7.11%
Mar 31, 2017 2.77%
Dec 31, 2016 12.46%
Sep 30, 2016 14.93%
Jun 30, 2016 19.30%
Mar 31, 2016 12.52%
Dec 31, 2015 19.11%
Sep 30, 2015 21.21%
Jun 30, 2015 25.64%
Mar 31, 2015 23.59%
Dec 31, 2014 26.80%
Sep 30, 2014 29.37%
Jun 30, 2014 18.31%
Mar 31, 2014 18.35%
Dec 31, 2013 10.36%
Sep 30, 2013 6.50%
Jun 30, 2013 5.21%
Mar 31, 2013 9.66%
Dec 31, 2012 11.13%
Sep 30, 2012 7.75%
Jun 30, 2012 6.60%
Mar 31, 2012 5.89%